Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.50 |
| ▸ | CNR1 | P21554 | 5/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 7/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SCARB1 | Q8WTV0 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2804380 | 0.99 | CNR2 (0.51) | CNR2CNR1PLA2G4AGAAKDM4E | |
| SCHEMBL2804613 | 0.83 | CNR2 (0.57) | CNR2CNR1PLA2G4ASCARB1 | |
| SCHEMBL2808362 | 0.76 | CNR2 (0.39) | CNR2CNR1KDM4EALDH1A1MAPT | |
| SCHEMBL2808266 | 0.73 | PLA2G4A (0.59) | PLA2G4AGAAMAPT | |
| SCHEMBL2809726 | 0.73 | PLA2G4A (0.61) | PLA2G4A | |
| SCHEMBL2804383 | 0.72 | GAA (0.40) | CNR2GAAKDM4EALDH1A1MAPT | |
| SCHEMBL28097123 | 0.72 | NR4A2 (0.65) | CNR2CNR1GAAALDH1A1MAPT | |
| SCHEMBL2806882 | 0.72 | PLA2G4A (0.45) | PLA2G4AKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL2804408 | 0.71 | PLA2G4A (0.46) | CNR2PLA2G4AKDM4E | |
| SCHEMBL3656961 | 0.71 | MEN1 (0.44) | GAAKDM4EALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240718-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVE, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 | WESTFALISCHE WILHELMS UNIVERSITÄT MÜNSTER (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240718-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVE, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 | PLD2, PLA2G1B, PLA2G4A | CNR2 60/4885CNR1 287/4885PLA2G4A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.